prolonged activation with high concentrations of ATP (3 mM) results in the formation of large nonselective membrane pores permeable to hydrophilic molecules of up to 900 Da (19) . These events are thought to cause subsequent changes in intracellular signaling and metabolic pathways leading to the activation of NF-B and stress-activated protein kinase (SAPK)/JNK, caspases, and cell apoptosis (16, 20 -22) . P2Y 2 receptors act via G proteins (G q ) to stimulate the phospholipase C␤ (PLC␤) signaling cascade, releasing Ca 2ϩ from internal stores (16, 23) . It has recently been reported that treatment of human M with ATP (ATP 4Ϫ ) potentiates M activity in killing of Mycobacterium tuberculosis (MTB) complex mycobacteria, such as MTB and Mycobacterium bovis bacillus Calmette-Guérin (BCG) (24 -28) . ATP-induced killing of mycobacterial organisms within M is principally mediated by P2X 7 receptors (24, 27) , although it has also been reported that purinergic signaling regulates M activity in killing of BCG organisms via a P2X 7 -independent mechanism (29) . In addition, ATP-mediated killing of mycobacterial organisms within M is mediated by phospholipase D, which is linked to leukocyte antimicrobial mechanisms dependent on the mobilization of intracellular Ca 2ϩ and subsequent lysosomal fusion and acidification of mycobacteria-containing phagosomes (25) (26) (27) .
These findings encouraged us to examine the effect of ATP administration to MAC-infected mice on the therapeutic efficacy of clarithromycin, a leading anti-MAC drug, in combination with rifamycin or the new benzoxazinorifamycin rifalazil (30) . We found that ATP significantly potentiated the therapeutic efficacy of clarithromycin/rifamycin (CR) in treating MAC-infected mice during the early stage of infection, principally by potentiating the anti-MAC activity of host M. In addition, we found that ATP-induced augmentation of M anti-MAC activity is dependent on type IV cytosolic phospholipase A 2 (cPLA 2 ), but not on reactive nitrogen intermediates (RNI) or reactive oxygen intermediates (ROI). It thus appears that arachidonic acid (AA), which results from cPLA 2 activity, plays an important role in ATP-induced potentiation of M antimycobacterial activity.
Materials and Methods

Organisms
MAC N-444 (serovar 8) and MAC N-260 (serovar 16) strains isolated from patients with MAC infection were used. These strains were identified as M. avium and M. intracellulare by DNA probe testing, respectively. Notably, the MAC N-260 strain is much more virulent to mice than the MAC N-444 strain (31) . The organisms were cultured in Middlebrook 7H9 broth, and bacterial suspension prepared with PBS containing 1% BSA was gently sonicated using a sonicator (model UR-20P; Tomy Seiko) for 5 s and centrifuged at 150 ϫ g for 5 min to eliminate bacterial clumps, and the upper layer (ϳ80% volume) was saved as an inoculum. In some experiments MTB H37Ra grown in 7H9 broth was used.
Mice
Five-week-old BALB/c mice were purchased from Japan Clea.
Special agents
Special agents used in this study were as follows: clarithromycin (Taisho Pharmaceutical), rifalazil (Kaneka), rifampin (Sigma-Aldrich), ATP (ICN Biomedicals), benzoylbezoic ATP (BzATP; Sigma-Aldrich), calcium ionophore A23187 (Sigma-Aldrich), N G -monomethyl-L-arginine (NMMA; Dojindo), manoalide (Wako Pure Chemical Industries), arachidonyl trifluoromethylketone (a-TFMK; Sigma-Aldrich), nordihydroguaiaretic acid (NDGA; Sigma-Aldrich), indomethacin (Sigma-Aldrich), and colchicine (Sigma-Aldrich), IFN-␥ (Genzyme Techne), superoxide dismutase (Wako Pure Chemical Industries), and catalase (Sigma-Aldrich). [ 3 H]AA and [ 3 H]oleic acid were purchased from American Radio-Labeled Chemicals.
Experimental infection
Six-week-old BALB/c mice infected i.v. with 1 ϫ 10 7 CFU of MAC were given, or not given, s.c. injections of clarithromycin (12 mg/kg) and rifampin (8 mg/kg) with or without simultaneous administration of ATP (40 mg/kg) s.c. once daily, five times per week, from day 1 after infection for up to 8 wk. Doses of test drugs were fixed to be nearly equivalent to their clinical dosages by weight. At intervals, mice were killed and examined for bacterial loads in the lungs and spleens by counting the number of CFU in the homogenates of individual organs using Middlebrook 7H11 agar plates.
Intracellular growth of MAC in M
M monolayer cultures prepared by seeding 1 ϫ 10 5 mouse RAW264.7 M (RAW-M) or 5 ϫ 10 4 J774.1 M (J774-M) on 96-well, roundbottom microculture wells were precultivated in 0.2 ml of RPMI 1640 medium containing 5% FBS and 25 mM HEPES at 37°C in a CO 2 incubator (5% CO 2 -95% humidified air) for 18 h. After washing with HBSS containing 2% FBS, the M were incubated in 0.1 ml of 5% FBS-RPMI 1640 medium containing 2 ϫ 10 7 CFU/ml MAC organisms (multiplicity of infection, 20) in a CO 2 incubator for 2 h. The MAC-infected M were then washed with 2% FBS-HBSS to remove extracellular organisms and thereafter cultivated in 0.2 ml of 5% FBS-RPMI 1640 medium with or without the addition of ATP, BzATP, A23187, or their combination in a CO 2 incubator for up to 6 days. In some experiments CR were added to the culture medium at the concentrations equivalent to their C max in the blood (clarithromycin, 2.3 g/ml; rifampin, 6.2 g/ml; rifalazil, 0.05 g/ml) of humans who were given clinical dosages of these drugs. At intervals, the M were lysed with 0.07% SDS, followed by subsequent neutralization with 6% BSA. After collection of bacterial cells from the resultant M lysate by centrifugation at 2000 ϫ g for 20 min and subsequent washing of recovered bacteria with distilled water by centrifugation, the number of CFU was counted on 7H11 agar plates.
Intracellular translocation of M membranous AA and oleic acid to infected mycobacterial organisms
Profiles of intracellular translocation of membranous AA and oleic acid to mycobacterial organisms internalized in M phagosomes were examined as described previously (32) . Briefly, zymosan A-induced mouse peritoneal exudate cells (2 ϫ 10 7 cells) were cultured in 10 ml of 5% FBS-RPMI 1640 medium on an FBS-coated plastic culture dish (80-mm diameter; Falcon) at 37°C in a CO 2 incubator for 2 h. After rinsing with 2% FBS-RPMI 1640, adherent cells consisting of Ͼ90% M were gently scraped off into 20% FBS medium with a rubber policemen and collected by subsequent centrifugation at 250 ϫ g for 5 min. Test M (6 ϫ 10 6 cells) were incubated in 3.0 ml of 5% FBS-RPMI 1640 containing 4 mCi/ml ]oleic acid were suspended in 200 ml of culture medium containing 1.0 ϫ 10 8 /ml MTB organisms and then incubated at 37°C for 2 h. After washing with 2% FBS-HBSS by centrifugation (120 ϫ g, 5 min) to remove extracellular organisms, infected M were cultivated at 37°C in a CO 2 incubator. After 12-h cultivation, M were collected, thoroughly washed with 2% FBS-HBSS, and lysed with 0.23% SDS solution for 10 min. Intramacrophage microorganisms were then collected by centrifugation (4200 ϫ g, 10 min), and the radioactivity of recovered microorganisms was measured using toluene-based scintillant containing Triton X-100 using a Tri-Carb liquid scintillation spectrometer (Packard Instrument).
Intracellular translocation of cPLA 2
Mouse peritoneal M (1 ϫ 10 6 cells) were seeded onto a 17-mm cover glass and cultured in 5% FBS-RPMI 1640 medium overnight using sixwell culture dishes (Corning). The resultant M monolayer was then infected with MAC N-260 by incubation in medium (5 ml) containing 1 ϫ 10 8 MAC (multiplicity of infection, 100) at 37°C for 2 h, then incubated in medium with or without addition of either ATP (3 mM) or BzATP (0.3 mM) at 37°C for 10 min. After fixation with 4% paraformaldehyde and then methanol, the M specimen was permeabilized with sequential treatments with 50 mM ammonium chloride for 10 min and 0.2% Triton X-100 for 10 min, and thereafter blocked with 2% BSA in PBS for 30 min, followed by subsequent treatment with anti-Fc mAb for 30 min. Immunolabeling was performed using the following Abs at 37°C for 2 h: 1) MAC staining: mouse anti-MAC mAb (primary Ab) and Alexa Fluor 546-conjugated goat anti-mouse IgG1 mAb (secondary Ab), each used at a dilution of 1/500; and 2) cPLA 2 staining: mouse anti-cPLA 2 mAb (primary Ab) and FITC-conjugated rat anti-mouse IgG2b mAb (secondary Ab), each used at a dilution of 1/100. All specimens were viewed on an Olympus FV300 digital fluorescence confocal laser scanning microscope. The cPLA 2 colocalization index, in terms of the relative intensity of cPLA 2 
Expression of cytokine mRNA
RT-PCR analysis of cytokine mRNAs in lung tissues from mice infected with MAC was performed as follows. Total RNA was isolated from the lung tissues of MAC-infected mice with or without drug treatment harvested wk 4 after infection using the ISOGEN kit (Nippon Gene). After DNase I (Invitrogen Life Technologies) treatment (1 U of DNase/g RNA sample) at room temperature for 15 min, the resultant RNA samples were reverse transcribed to the first chain of cDNA using random hexamer primers ( 
Statistical analysis
Statistical analysis was performed using a one-way ANOVA with a Bonferroni multiple comparisons post-test (StatView software; Hulinks).
Results
Effect of ATP administration on the therapeutic efficacy of CR against MAC infection
First, we examined the effects of ATP administration on MACinfected mice, which were, or were not, given antimycobacterial CR drug regimens, on bacterial behavior at sites of infection (lungs and spleen). Fig. 1 shows the profiles of bacterial growth during the 4-wk period following infection in the lungs and spleens of MAC-infected mice, which were, or were not, treated with ATP, CR, or both. As shown in Fig. 1 , A and B, in mice infected with the MAC N-444 strain (low virulence), persistent infection without bacterial growth was observed in the lungs, and gradual bacterial growth was noted in the spleen. ATP (50 mg/kg) alone did not affect the profiles of bacterial persistence in the lungs, whereas ATP in combination with CR (20 and 5 mg/kg, respectively) potentiated the bacterial elimination in the lungs due to the CR drug regimen (Fig. 1A) . In the spleen, ATP alone slightly decreased the bacterial load at wk 4, whereas ATP in combination with CR enhanced CR-mediated bacterial elimination during wk 2-4 ( Fig. 1B) .
As shown in Fig. 1 , C and D, in mice infected with the MAC N-260 strain (high virulence), significant levels of bacterial growth were observed in the lungs and spleen at wk 4 after infection. ATP alone did not affect bacterial growth in the lungs (Fig. 1C, u) , but completely inhibited growth of MAC in the spleen (Fig. 1D, u) . Administration of ATP in combination with CR caused more potent growth inhibition of the organisms in the lungs than that in mice given CR alone (Fig. 1C, f) . As shown in Fig. 1D , bacterial elimination was clearly observed in the spleens of mice given ATP in combination with CR (f), whereas CR alone caused only growth inhibition of MAC (o). Fig. 2 shows histopathological examination of the lungs of infected mice given, or not given, ATP. In mice without ATP treatment, a number of tubercular lesions consisting of epithelioid-like M surrounded by infiltrating lymphocytes were observed, but no caseous necrosis was noted ( (Fig. 2E ). In contrast, CR significantly decreased the number of tubercular lesions (photo not shown), and the number of granulomas was 0.16 Ϯ 0.02/mm 2 field (Fig. 2E ). These findings suggest that ATP treatment affects neither the formation nor the progression of granulomatous lesions in MAC-infected mice, unlike antimicrobial drugs.
We next examined profiles of the mRNA expression of cytokines that up-regulate M antimycobacterial activity (TNF-␣, IFN-␥, and IL-2) and those that down-regulate it (IL-4, IL-10, IL-13, and TGF-␤) (33) in the lungs of infected mice given, or not given, CR with or without ATP at wk 4 after infection. As shown in Fig. 3 , TNF-␣ mRNA expression was not changed due to MAC infection, but was markedly decreased by administration of CR. In contrast, IFN-␥ mRNA expression was up-regulated due to MAC infection, but was not affected by administration of CR. The expression of both IL-10 mRNA and IL-13 mRNA was markedly decreased by MAC infection. In these cases, administration of CR did not affect the mRNA expression of these cytokines. In contrast, TGF-␤ mRNA expression was slightly decreased in MAC-infected mice, but was not affected by administration of CR. Notably, ATP administration did not affect the profiles of mRNA expression of these cytokines in mice given CR alone. Neither IL-2 nor IL-4 mRNA expression was observed with any of the regimens tested (data not shown). These findings indicate that ATP administration did not modulate Th1 and Th2 cytokine gene expression in lungs of MAC-infected mice treated with CR.
Effects of ATP on antimicrobial activity of CR against intramacrophage MAC
To clarify the cellular mechanisms of the ATP-mediated increase in the in vivo efficacy of CR chemotherapy against MAC infection in mice, we examined the effects of high concentrations of ATP on the antimicrobial activity of M (RAW-M and J774-M) against MAC organisms (N-444 and N-260 strains). As indicated in Fig.  4A , ATP at 10 mM, but not at 3 mM, weakly, but significantly, inhibited the growth of the low virulence MAC N-444 strain (31) in RAW-M. Notably, both concentrations (3 and 10 mM) of ATP tested markedly potentiated the bactericidal activity of CR at the C max in blood against the MAC organisms residing within RAW-M. As shown in Fig. 4B , in the case of RAW-M infected with the high virulence MAC N-260 strain (31) , ATP at 3 and 10 mM did not reduce, but, in fact, somewhat enhanced, the intramacrophage growth of organisms. These results, therefore, demonstrate that ATP exerts its antimicrobial activity against intramacrophage MAC mostly in the presence of antimycobacterial drugs. Nevertheless, both concentrations of ATP significantly augmented the bactericidal activity of CR against intramacrophage MAC. Fig. 4C shows the results of a similar experiment using J774-M. In this case, ATP alone or in combination with CR exhibited similar effects on the behavior of intramacrophage MAC N-444 organisms, as in the case of RAW-M shown in Fig. 4A . In this context, separate experiments showed that 10 mM ATP did not significantly augment the antimicrobial activity of CR against extracellular MAC when the organisms growing in 7HSF medium were treated with CR (1/2 C max each) in combination with ATP during 4-day culture. In a representative experiment, log-unit values of the bacterial CFU after 4-day culture (n ϭ 3) were as follows: day 0, 4.41 Ϯ 0.01; [1] , clarithromycin/rifampin, 2.08 Ϯ 0.02; clarithromycin/rifampin plus ATP, 1.73 Ϯ 0.03; and [2] , clarithromycin/rifalazil, 1.63 Ϯ 0.23; clarithromycin/rifalazil plus ATP, 1.80 Ϯ 0.41. Therefore, it appears that ATP, even at 10 mM, does not affect the antimicrobial activity of CR against extracellular MAC.
Intracellular mechanisms of ATP-dependent potentiation of the antimicrobial activity of CR against intramacrophage MAC
Next we attempted to clarify the intracellular mechanisms of the ATP-mediated potentiation of antimicrobial activity of CR against MAC organisms residing inside M. First, as shown in Fig. 5A , we found that the combination of ATP at a suboptimal concentration (0.3 mM) with calcium ionophore A23187 significantly potentiated M anti-MAC activity, although ATP alone was ineffective in increasing this activity. Next, we examined the effects of ATP and BzATP (a potent P2X 7 receptor agonist) on the anti-MAC antimicrobial activity of M cultivated in medium in the presence of ionophore A23187 with or without the addition of CR. In this experiment, RAW-M were treated with IFN-␥ (500 U/ml) for 24 h, and the same concentration of IFN-␥ was added to the culture medium of MAC-infected M. In this case, ATP and BzATP at a suboptimal concentration (0.3 mM) failed to potentiate M antimicrobial activity against intracellular MAC, even after stimulation of M with IFN-␥, which is known to increase M sensitivity to ATP-mediated induction of M apoptosis and cause concomitant expression of M antimycobacterial activity (24) (data not shown). However, as shown in Fig. 5B , when the M were treated with the Ca 2ϩ ionophore A23187 in combination with either ATP or BzATP at a suboptimal concentration (0.3 mM), significant bacterial killing of intramacrophage MAC was observed. This finding supports previous observations by Stober et al. (26) and Kusner and Barton (28) that ATP-mediated killing of mycobacteria within M is dependent on intracellular Ca 2ϩ mobilization. In this case, the bactericidal activity of CR against intramacrophage MAC was further potentiated by BzATP, but not by ATP. This finding indicates that extracellular ATP augments the antimicrobial activity of CR against intramacrophage MAC activity organisms, specifically through P2X 7 receptors.
Next we examined the roles of ROI, RNI, and AA in the effector pathway(s) involved in the ATP-dependent increase in CR antimicrobial activity against intramacrophage MAC organisms, that is, ATP-mediated potentiation of M anti-MAC activity with culture in the presence of CR. As shown in Fig. 5C (right columns) , the potentiation by ATP at an optimal concentration (10 mM) of the antimicrobial activity of CR against intramacrophage MAC was markedly abrogated by a-TFMK (cPLA 2 inhibitor), but not by superoxide dismutase/catalase (ROI scavengers) or NMMA (iNOS inhibitor). These findings suggest that cPLA 2 -mediated release of AA into MAC-containing phagosomes may play an important role in ATP-mediated potentiation of M anti-MAC activity in the presence of CR.
In this context, we previously found that in the case of [ 3 H]AAlabeled M, membranous radioactive component(s) (presumably [ 3 H]AA) translocated to the microorganisms internalized within M phagosomes (32) . As shown in Fig. 5D , the translocation of the [ 3 H]labeled membranous component(s) to intramacrophage mycobacteria was almost completely inhibited by a-TFMK and colchicine (an inhibitor of phagocytosis), but not by manoalide (a secretory PLA 2 inhibitor), NDGA (a lipoxygenase inhibitor), or indomethacin (a cyclooxygenase inhibitor). Moreover, AA directly bound to mycobacterial cell bodies (Fig. 5E ). These findings indicate the following. First, it has been reported that the ED 50 of indomethacin for the inhibition of PG synthesis by zymosan Astimulated M was only 0.01 M (34, 35) , and indomethacin at 10 M caused 99% inhibition of PG production by LPS-stimulated M (36) . In addition, the ED 50 values of NDGA for the inhibition of PG and leukotriene synthesis by zymosan A-stimulated M were 3 and 7 M, respectively (34, 35) . Therefore, it is believed that both indomethacin and NDGA at the concentration (20 M) used in the present study are able to effectively inhibit M PG and/or leukotriene synthesis. It thus appears that 3 H-labeled AA, but neither 3 H-labeled leukotrienes nor PGs/thromboxanes (lipoxygenase-and cyclooxygenase-catalyzed metabolites of AA, respectively), translocated to intracellular mycobacteria in host M. Second, the AA translocation was principally mediated by cPLA 2 and was associated with M bacterial phagocytosis. It thus appears that ATP signaling causes cPLA 2 activation via the intracellular Ca 2ϩ mobilization pathway, thereby enhancing the cPLA 2 -mediated release of AA, one of the major antimycobacterial effectors of M (32, 37-39), into MAC-containing M phagosomes. Fig. 6 shows profiles of the localization of cPLA 2 in MACinfected M that were cultured in the presence or the absence of ATP (3 mM) or BzATP (0.3 mM). First, in uninfected M cultured in the absence of ATP or BzATP, trace amounts of cPLA 2 were diffusely expressed in the cytoplasm (Fig. 6b) . Second, in MAC-infected M cultured in the absence of ATP or BzATP, moderately increased cPLA 2 expression was observed in the cytoplasm (Fig. 6e) . In this case, cPLA 2 did not condense around intraphagosomal MAC organisms (Fig. 6, d and f) . Third, in MACinfected M cultured in the presence of ATP or BzATP, potently increased cPLA 2 expression was noted (Fig. 6, h and k) . In these cases, a part of cPLA 2 was intensely condensed around intraphagosomal MAC organisms (Fig. 6, g, i and j, l, respectively) . In this experiment, the cPLA 2 colocalization indexes, in terms of the relative intensity of cPLA 2 fluorescence colocalizing with intracellular MAC organisms, was estimated as follows (n ϭ 30): MAC infection alone (control; Fig. 6, d-f) , 0.57 Ϯ 0.02; MAC infection plus ATP treatment (Fig. 6, g-i) , 1.18 Ϯ 0.02 (significantly greater than the control, p Ͻ 0.01); and MAC infection plus BzATP treatment (Fig. 6, j-l ), 1.10 Ϯ 0.03 (significantly greater than the control, p Ͻ 0.01). It thus appears that in MAC-infected M, ATP signaling via P2X 7 receptors induces cPLA 2 translocation to the phagosomal membranes surrounding internalized MAC organisms.
Discussion
The major findings of this study can be summarized as follows. 1) Administration of ATP in combination with the CR drug regimen accelerated bacterial elimination in MAC-infected mice without causing changes in the histopathological features or the expression of pro-and anti-inflammatory cytokine genes from those in mice not given ATP. 2) ATP potentiated the anti-MAC bactericidal activity of host M cultivated in the presence of clarithromycin and rifamycin. This effect of ATP was dependent on intracellular Ca 2ϩ mobilization and cPLA 2 , which generates AA from phospholipids. 3) Intramacrophage translocation of membranous AA molecules to MAC-containing phagosomes was also mediated by cPLA 2 . Notably, ATP enhanced the intracellular translocation of cPLA 2 into MAC-containing phagosomes. Concerning these findings, the following discussion can be made. First, it is somewhat strange that ATP treatment potentiated the ability of MAC-infected mice to decrease bacterial loads, especially when infected mice were given the CR drug regimen, without affecting the formation/progression of granulomatous lesions and cytokine gene expression in the lungs of infected mice. Thus, it appears that ATP may principally enhance the host innate immunity that is much less dependent on Th1 cytokine-mediated granuloma formations than is the case for acquired cellular immunity against mycobacterial Ags.
Second, the present findings also indicate that ATP potentiates M antimicrobial activity against not only MTB complex mycobacteria (MTB and M. bovis BCG) (24, 25) , but also MAC mycobacteria, especially when infected M are cultured in the presence of CR. However, it was noted that MAC organisms, particularly those of the high virulence N-260 strain, were much more resistant to the ATP-induced antimicrobial activity of M than was MTB complex (Fig. 4) . This may mean that the M antimicrobial mechanisms required for the killing/inhibition of MAC are somewhat different from those required for the killing/ inhibition of the MTB complex. As indicated in Fig. 5A , M exhibited potentiation of anti-MAC activity in response to ATP signaling at suboptimal concentration (0.3 mM) only when Ca 2ϩ ionophore A23187-mediated cytosolic Ca 2ϩ mobilization was provided. In this context, an increased cytosolic Ca 2ϩ concentration is known to promote the maturation of phagosomes containing mycobacterial organisms and thereby potentiate M activity in killing/inhibiting intraphagosomal mycobacteria (40) . It thus appears that ATP signaling at suboptimal concentrations via P2Y may mobilize intramacrophage signal transduction pathways independent of cytosolic Ca 2ϩ mobilization. In contrast, the intracellular signaling pathways induced by ATP signaling at optimal concentrations (3-10 mM) are known to 3 mM) , or CR (clarithromycin, 2.3 g/ml; rifampin, 6.2 g/ml), alone or together for 5 days. C, Influences of ROI scavengers (superoxide dismutase/catalase (SOD/CAT)), iNOS inhibitor (NMMA), and cPLA 2 inhibitor (a-TFMK) on the effects of ATP in potentiating M anti-MAC antimicrobial activity. MAC N-444-infected RAW M were cultured in the absence or the presence of ATP (10 mM) or CR (clarithromycin, 2.3 g/ml; rifalazil, 0.05 g/ml) alone or in combination with superoxide dismutase (1000 U/ml) plus catalase (900 U/ml), NMMA (0.5 mM), or a-TFMK (10 M) for 5 days. Solute control (0.1% DMSO), SOD/CAT, NMMA, or a-TFMK alone exerted no influence on the intramacrophage growth of the organisms. D, cPLA 2 -and phagocytosisdependent translocation of M membranous AA to mycobacterial organisms internalized in phagosomal vesicles. (n ϭ 4) . The asterisks denote a statistically significant difference between two specified groups ‫,ء(‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01). These data represent one of two or three experiments that were performed with similar results.
involve Ca 2ϩ mobilization, followed by the activation of phospholipase D, leading to phagosome-lysosome fusion and acidification of mycobacteria-containing phagosomes (25) (26) (27) (28) . In addition, a recent finding by Vergne et al. (41) indicated that Ca 2ϩ and calmodulin are required for a Ca 2ϩ /calmodulin PI3K hVPS34 cascade essential for the production of phosphatidylinositol 3-phosphate on phagosomes and, consequently, maturation of phagosomes. As shown in Fig. 5A , mobilization of Ca 2ϩ -dependent signaling pathways did not fully support effective M killing of MAC organisms, although it has been reported that such cellular events were sufficient for rapid killing of the MTB complex (24 -28) . Notably, we previously obtained evidence that the modes of interaction of MAC with the antimicrobial mechanisms of M differ considerably from those of MTB. In bacterial killing experiments in a cell-free system, although RNI in combination with an H 2 O 2 -Fe 2ϩ -mediated halogenation system exhibited synergistic anti-MTB activity, the same regimen exhibited an antagonistic effect on MAC organisms (32, 39) .
Third, with respect to antimicrobial effector molecules of host M against mycobacterial organisms, the following concepts have been generally accepted (42, 43) . First, concerning ROI, wellknown effectors of M antimicrobial activity against some intracellular bacteria, such as Listeria monocytogenes and Salmonella Typhimurium, their participation in killing and growth inhibition of mycobacteria is reported to be relatively small (42) (43) (44) . Next, RNI are reported to be the principal effectors of murine M in antimicrobial functions against MTB (42, 44) . Although more controversial in human M, there is increasing evidence that RNI produced by MTB-infected M have anti-MTB antimicrobial activity (42) . Nevertheless, some controversial findings have been reported on the role of RNI as the major antimycobacterial effectors of host Ms, as follows (38) . 1) Gomes et al. (45) reported that M from mice genetically deficient in the iNOS were equally able to restrict MAC growth in vitro after stimulation by IFN-␥ and TNF-␣ as M from wild-type mice. Moreover, they found that the MAC infection progressed at similar rates in wild-type and iNOSdeficient mice during the first 2 mo of infection, but the latter mice were subsequently more efficient in clearing the MAC than the former mice (45) . This implies that RNI is not involved in the antimycobacterial mechanisms of MAC-infected M.
2) It has been found that osteopontin-mediated facilitation of bacterial clearance of BCG organisms in infected mice was independent of RNI production (46). 3) As reported by Lammas et al. (24) , neither RNI nor ROI played any critical role in the expression of antimicrobial activity against BCG organisms by human monocyte-derived M, which was given ATP signaling via P2X 7 receptors. These findings strongly suggest the possibility that the RNI-and ROI-independent antimycobacterial mechanism(s) may be crucial for the antimycobacterial function of host M.
In this context, we previously found that free fatty acids (such as AA and linolenic acid) exhibited potent antimicrobial activity against mycobacterial organisms, including MTB and MAC (32, 39) . In addition, free fatty acids in combination with RNI played critical roles in manifestation of the activity of M against mycobacterial pathogens, including MTB and MAC (32, 39, 47) . The important roles of free fatty acids, such as AA and oleic acid, which are the major unsaturated fatty acyl residues of M membrane phospholipids (48) , in the antimycobacterial mechanisms of host M are also supported by the following findings (32, 39) . 1) MTB-or MAC-infected M sequentially produced/released free fatty acid (AA) and subsequently RNI. 2) Sequential treatment of mycobacterial organisms with AA, then RNI, caused synergistic bactericidal activity against these pathogens. 3) In the case of [ 3 H]AA-labeled M, membranous radioactivity (presumably that of [ 3 H]AA) was found to translocate to intraphagosomal microorganisms during chase incubation after MTB infection. 4) M antimicrobial activity against MTB was strongly inhibited by a-TFMK (cPLA 2 inhibitor). Moreover, as indicated in Fig. 5D , the present study also revealed that the intramacrophage translocation of membranous AA molecules to intraphagosomal MAC organisms was specifically blocked by a-TFMK. These findings strongly suggest that free fatty acids (especially AA) produced by the enzymatic action of cPLA 2 play an important role as antimycobacterial effectors in the expression of M antimicrobial activity against mycobacterial pathogens. This concept is in part supported by the finding of Duan et al. (49) that the apoptosis-mediated expression of anti-MTB antimicrobial activity of human monocytederived M was dependent on cPLA 2 2 . These findings indicate that intramacrophage AA mobilization is mediated by cPLA 2 in a specific fashion, although not only AA, but also oleic acid, play important roles in the expression of M antimicrobial activity against intracellular mycobacterial organisms.
In the present study it was found that ATP-induced potentiation of M anti-MAC activity in the presence of CR was almost completely abolished by a cPLA 2 inhibitor, a-TFMK, but not by ROI scavengers or iNOS inhibitor (Fig. 5C ). This indicates that the anti-MAC bactericidal activity of ATP-stimulated M is primarily mediated by a free fatty acid, AA, released by cPLA 2 from phospholipids of the phagosomal membrane. In addition, we found that in MAC-infected M, ATP signaling induced intracellular translocation/condensation of cPLA 2 molecules to phagosomes surrounding internalized MAC organisms (Fig. 6 ). To our knowledge, this is the first report that demonstrated intracellular translocation of cPLA 2 to intraphagosomal mycobacterial organisms and possible roles of cPLA 2 in intraphagosomal bacterial killing in ATPtreated M during the course of mycobacterial infection. Because serine phosphorylation of cPLA 2 molecules (especially of Ser 505 ) is known to promote membrane penetration of hydrophobic amino acid residues in their active site rim (50), the cPLA 2 condensation to phagosomal membranes in response to ATP signaling (Fig. 6 ) also appears to be related to the serine phosphorylation of cPLA 2 . Indeed, it was reported that ATP treatment of M resulted in the activation of cPLA 2 due to MAPK/ERK1,2-mediated phosphorylation of serine residues (51) (52) (53) . In separate experiments, ATPinduced expression of potentiated anti-MAC activity was found to be associated with apoptotic cell death of ATP-treated M (H. Tomeoka, K. Sato, C. Sano, and T. Shimizu, unpublished observation), as previously reported for BCG-infected M (24, 27) . This is consistent with the finding by Duan et al. (49) that MTB induced M apoptosis through at least two types of signaling pathways, TNF-␣-or cPLA 2 -dependent cascades, each of which is also crucial for M antimycobacterial defense mechanisms. In any case, these findings clearly indicate that ATP-mediated bacterial killing in MAC-infected M is strictly dependent on cPLA 2 functions and its metabolic product, AA, but is substantially independent of RNI and ROI. This finding strongly supports that concept that AA generated by the enzymatic action of cPLA 2 plays a critical role in the antimycobacterial mechanisms of host M.
Fourth, high concentrations of ATP (3-10 mM) were required to achieve significant levels of M anti-MAC activity even in the case of the low virulence MAC (N-444 strain)-infected M and to yield clear potentiation of M anti-MAC activity in the presence of CR (Fig. 4) . This implies that ATP acts via P2X 7 receptors to induce/potentiate M anti-MAC activity, because the active component of ATP interacting with P2X 7 receptors is the fully ionized form of ATP (ATP 4Ϫ ), which is present as a small fraction of ATP at physiological pH. This conclusion is supported by the finding that these effects were mimicked by BzATP, a known agonist of P2X7 receptors (Fig. 5B) . As shown in Fig. 5A , Ca 2ϩ mobilization was required for M to display significant levels of anti-MAC activity when ligation of P2 receptors of MAC-infected M was provided by a low concentration of ATP (0.3 mM). Under these conditions, P2Y receptors (presumably P2Y 2 and/or P2Y 11 receptors) might participate in ATP-induced anti-MAC activity of M by activating PLC␤, which is coupled with PKC activation, and subsequent activation of MAPK-mediated cPLA 2 activation (53).
Fifth, another important finding of the present study is that ATP strongly potentiated M anti-MAC antimicrobial functions when M were treated with CR, a combination of anti-MAC antimicrobial drugs (clarithromycin plus rifamycin). It thus appears that the use of ATP in combination with certain antimycobacterial drugs, including macrolides and rifamycins, may be beneficial in achieving efficacious control of patients with intractable MAC infections. ATP is an essential compound for all living things and can be administered to humans without severe adverse effects. At present, ATP is safely used as a vasodilator for clinical control of ischemia in the coronary arteries and paroxysmal tachycardia (54, 55) . It thus appears that ATP can be safely administered to MAC patients.
There have been a number of attempts to establish efficacious regimens of adjunctive immunotherapy for management of patients with mycobacterial infections involving administration of certain immunomodulators in combination with antimycobacterial drugs (33) . Adjunctive clinical trials using IL-2 or GM-CSF found these agents to be efficacious to some extent in improving patients with tuberculosis or disseminated MAC infections (33) . However, these immunomodulating cytokines as well as IFN-␥ and IL-12 do not appear promising as therapeutic agents for mycobacterial infections because of the possibility of induction of immunosuppressive cytokines, such as TGF-␤, IL-10, and IL-13, during adjuvant therapy and, in some cases, severe adverse effects (33) . Thus, the development of new classes of immunomodulators other than cytokines, particularly those with no severe adverse effects, is needed. In this context, ATP may be one of the most promising agents for clinical immunotherapy of mycobacterial infections in combination with anti-MAC chemotherapy for the following reasons. First, it is safe for humans, as described above. Second, ATP acts directly on M and rapidly causes not only potentiation of M antimycobacterial activity, but also concomitant apoptosis of M. It thus appears that ATP-stimulated M do not serve as a cell source of immunosuppressing cytokines, which suppress M antimycobacterial functions in an autocrine or paracrine fashion. Indeed, in the present study prolonged ATP administration (4 wk) did not increase the mRNA expression of these immunosuppressing cytokines (Fig. 3 ). It will be of interest to examine the therapeutic effects of regimens involving ATP in combination with macrolides (clarithromycin and azithromycin), rifamycins (rifampin, rifabutin, and rifalazil), and other drugs (ethambutol, streptomycin, and quinolones) against MAC infections over long observation periods at least 16 wk after infection. Additional studies are currently underway to elucidate the usefulness of ATP therapy of MAC infection in detail.
